Comment:
“While clinicians cannot specifically control how the pharmaceutical industry sets prices for medications, we welcome any steps that increase access to agents to prevent cardiovascular events in patients with established cardiovascular disease.”

Keith C. Ferdinand, MD FACC, FAHA
Professor,Tulane University SOM
Chair, ABC Access Initiative

New Option Should Lower Out-of-Pocket Costs for America’s Seniors at Risk for Heart Attacks and Strokes

THOUSAND OAKS, Calif., Oct. 24, 2018 – Amgen (NASDAQ:AMGN) announced that it is making Repatha^® (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price of $5,850 per year. This 60 percent reduction from the medicine’s original list price will improve affordability by lowering patient copays, especially for Medicare patients.